Vaxzevria Vaccine is used to prevent coronavirus disease 2019 (COVID-19) in people from 18 years of age. It has been designed to prepare the immune system to identify and combat the coronavirus SARS-CoV-2 causing COVID-19.

The vaccine is made up of a chimpanzee adenovirus (ChAdOx1 - Chimpanzee Adenovirus Oxford 1) that is unable to replicate and that has been modified to contain the genetic information for producing the SARS-CoV-2 spike protein.

The viral vector technology used for this vaccine has already been successfully tested and has been employed in the prevention of other diseases.

The European Commission withdrew the marketing authorisation for Vaxzevria (COVID
19 Vaccine in the European Union (EU) at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.